| dbo:abstract |
Relugolix ist ein Arzneistoff zur Behandlung von bösartigen Tumoren (Krebs), die hormonempfindlich sind. Er wird angewendet zur Behandlung des fortgeschrittenen Prostatakrebses. Er kommt ferner zum Einsatz zur Linderung von mäßigen bis starken Symptomen bei Gebärmuttermyomen und experimentell bei Endometriose, einer Erkrankung, bei der gebärmutterschleimhautartiges Gewebe außerhalb der Gebärmutterhöhle vorkommt. Relugolix wirkt als und kann oral gegeben (eingenommen) werden. (de) Relugolix, sold under the brand names Orgovyx and Relumina and as one component of Myfembree, is a gonadotropin-releasing hormone antagonist (GnRH receptor antagonist) medication which is used in the treatment of prostate cancer in men and uterine fibroids in women. It is also under development for use in the treatment of endometriosis. It is taken by mouth once per day. Side effects of relugolix include menstrual abnormalities, hot flashes, excessive sweating, headache, and decreased bone mineral density. Relugolix is a GnRH antagonist, or an antagonist of the gonadotropin-releasing hormone receptor. Unlike most other GnRH modulators, but similarly to elagolix (brand name Orilissa), relugolix is a non-peptide, small-molecule compound and is orally active. It suppresses sex hormone levels to the postmenopausal or castrate range in both women and men with administration once per day. As of February 2019, relugolix is in phase III clinical trials for endometriosis. It was approved for use for the treatment of uterine fibroids in Japan in January 2019, and for the treatment of prostate cancer in the United States in December 2020. (en) |
| dbo:alternativeName |
Orgovyx, Relumina (en) |
| dbo:atcCode |
(combination withestradiolandnorethisterone) |
| dbo:casNumber |
737789-87-6 |
| dbo:chEMBL |
1800159 |
| dbo:class |
dbr:GnRH_antagonist |
| dbo:drugbank |
DB11853 |
| dbo:fdaUniiCode |
P76B05O5V6 |
| dbo:kegg |
D10888 |
| dbo:pubchem |
10348973 |
| dbo:thumbnail |
wiki-commons:Special:FilePath/Relugolix_structure.png?width=300 |
| dbo:wikiPageExternalLink |
https://druginfo.nlm.nih.gov/drugportal/name/relugolix |
| dbo:wikiPageID |
48188195 (xsd:integer) |
| dbo:wikiPageLength |
22350 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1082623023 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbc:Pyridazines dbr:Progesterone dbr:Non-peptide dbr:Hyperhidrosis dbr:Urea dbr:Menopause dbc:Dimethylamino_compounds dbc:Ethers dbc:Fluoroarenes dbc:Triketones dbc:Ureas dbr:Chemical_compound dbr:Oral_administration dbr:Elagolix dbr:Elimination_half-life dbr:Endometriosis dbr:Gonadotropin-releasing_hormone_antagonist dbr:Clinical_trial dbr:Committee_for_Medicinal_Products_for_Human_Use dbr:Feces dbr:Hot_flash dbr:Receptor_antagonist dbr:Phenyl_group dbr:Prostate_cancer dbr:Substrate_(biochemistry) dbc:Hormonal_antineoplastic_drugs dbr:Distribution_(pharmacology) dbr:Loading_dose dbr:Estradiol dbr:Ethinyl_estradiol dbr:European_Medicines_Agency dbr:Follicle-stimulating_hormone dbr:Absorption_(pharmacokinetics) dbr:Norethindrone dbr:Norethisterone dbr:Osteoporosis dbr:Gonadotropin-releasing_hormone_receptor dbr:Generic_term dbr:Uterine_fibroid dbc:Pyrimidines dbr:Headache dbr:Testosterone dbc:GnRH_antagonists dbr:Abnormal_uterine_bleeding dbr:Binding_selectivity dbr:Bioavailability dbr:Tablet_(pharmacy) dbr:Takeda_Pharmaceutical_Company dbr:Cmax_(pharmacology) dbr:CYP3A4 dbr:GnRH_modulator dbr:Menopausal_symptoms dbr:Menstrual_abnormalities dbr:Castration dbr:Sex_hormone dbr:Side_effect dbr:Urine dbr:Luteinizing_hormone dbr:Phases_of_clinical_research dbr:Plasma_protein_binding dbr:Sufugolix dbr:Excretion dbr:P-glycoprotein dbr:Menorrhagia dbr:Half-maximal_inhibitory_concentration dbr:Postmenopause dbr:Hot_flush dbr:Steady-state_levels dbr:GnRH_analogue dbr:GnRH_antagonist dbr:Chemical_derivative dbr:Small-molecule dbr:Myovant_Sciences dbr:Estrogen_deficiency dbr:Interindividual_variability dbr:File:Estradiol_levels_with_40_mg_per_d...ix_therapy_in_premenopausal_women.png |
| dbp:atcPrefix |
L02 (en) |
| dbp:atcSuffix |
BX04 (en) |
| dbp:c |
29 (xsd:integer) |
| dbp:casNumber |
737789 (xsd:integer) |
| dbp:chembl |
1800159 (xsd:integer) |
| dbp:chemspiderid |
8524431 (xsd:integer) |
| dbp:class |
dbr:GnRH_antagonist |
| dbp:dailymedid |
Relugolix (en) |
| dbp:drugbank |
DB11853 (en) |
| dbp:eliminationHalfLife |
234000.0 (dbd:second) |
| dbp:excretion |
Feces: 82% (en) Urine: 4% (en) |
| dbp:f |
2 (xsd:integer) |
| dbp:h |
27 (xsd:integer) |
| dbp:image |
Relugolix molecule ball.png (en) |
| dbp:iupacName |
1 (xsd:integer) |
| dbp:iupharLigand |
5586 (xsd:integer) |
| dbp:kegg |
D10888 (en) |
| dbp:legalUs |
Rx-only (en) |
| dbp:n |
7 (xsd:integer) |
| dbp:o |
5 (xsd:integer) |
| dbp:proteinBound |
68 (xsd:integer) |
| dbp:pubchem |
10348973 (xsd:integer) |
| dbp:routesOfAdministration |
dbr:Oral_administration |
| dbp:s |
1 (xsd:integer) |
| dbp:smiles |
CONCNc1ccccc1 (en) |
| dbp:stdinchi |
1 (xsd:integer) |
| dbp:stdinchikey |
AOMXMOCNKJTRQP-UHFFFAOYSA-N (en) |
| dbp:synonyms |
RGX; RVT-601; TAK-385 (en) |
| dbp:tradename |
Orgovyx, Relumina (en) |
| dbp:unii |
P76B05O5V6 (en) |
| dbp:width |
250 (xsd:integer) |
| dbp:wikiPageUsesTemplate |
dbt:GnRH_and_gonadotropin_receptor_modulators dbt:Cite_journal dbt:Cite_web dbt:Drugbox dbt:Portal_bar dbt:Reflist dbt:Short_description dbt:Abbrlink dbt:Fdacite dbt:ATC dbt:ClinicalTrialsGov dbt:GnRH_and_gonadotropins dbt:Pituitary_and_hypothalamic_hormones_and_analogues |
| dct:subject |
dbc:Pyridazines dbc:Dimethylamino_compounds dbc:Ethers dbc:Fluoroarenes dbc:Triketones dbc:Ureas dbc:Hormonal_antineoplastic_drugs dbc:Pyrimidines dbc:GnRH_antagonists |
| gold:hypernym |
dbr:Antagonist |
| rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug |
| rdfs:comment |
Relugolix ist ein Arzneistoff zur Behandlung von bösartigen Tumoren (Krebs), die hormonempfindlich sind. Er wird angewendet zur Behandlung des fortgeschrittenen Prostatakrebses. Er kommt ferner zum Einsatz zur Linderung von mäßigen bis starken Symptomen bei Gebärmuttermyomen und experimentell bei Endometriose, einer Erkrankung, bei der gebärmutterschleimhautartiges Gewebe außerhalb der Gebärmutterhöhle vorkommt. Relugolix wirkt als und kann oral gegeben (eingenommen) werden. (de) Relugolix, sold under the brand names Orgovyx and Relumina and as one component of Myfembree, is a gonadotropin-releasing hormone antagonist (GnRH receptor antagonist) medication which is used in the treatment of prostate cancer in men and uterine fibroids in women. It is also under development for use in the treatment of endometriosis. It is taken by mouth once per day. (en) |
| rdfs:label |
Relugolix (de) Relugolix (en) |
| owl:sameAs |
yago-res:Relugolix wikidata:Relugolix dbpedia-de:Relugolix dbpedia-fa:Relugolix https://global.dbpedia.org/id/zT3n |
| prov:wasDerivedFrom |
wikipedia-en:Relugolix?oldid=1082623023&ns=0 |
| foaf:depiction |
wiki-commons:Special:FilePath/Estradiol_levels_with...ix_therapy_in_premenopausal_women.png wiki-commons:Special:FilePath/Relugolix_molecule_ball.png wiki-commons:Special:FilePath/Relugolix_structure.png |
| foaf:isPrimaryTopicOf |
wikipedia-en:Relugolix |
| is dbo:wikiPageRedirects of |
dbr:ORGOVYX dbr:Orgovyx dbr:Relumina dbr:RVT-601 dbr:RVT601 dbr:RVT_601 dbr:TAK-385 dbr:TAK385 dbr:TAK_385 |
| is dbo:wikiPageWikiLink of |
dbr:Relugolix/estradiol/norethisterone_acetate dbr:ORGOVYX dbr:Elagolix dbr:Gonadotropin-releasing_hormone_antagonist dbr:Feminizing_hormone_therapy dbr:Gonadotropin-releasing_hormone_modulator dbr:Gonadotropin-releasing_hormone_receptor dbr:ATC_code_H01 dbr:ATC_code_L02 dbr:Sufugolix dbr:Orgovyx dbr:Relumina dbr:RVT-601 dbr:RVT601 dbr:RVT_601 dbr:TAK-385 dbr:TAK385 dbr:TAK_385 |
| is owl:differentFrom of |
dbr:RGX |
| is foaf:primaryTopic of |
wikipedia-en:Relugolix |
